Adherence to lupus medications associated with lower diabetes risk

The results of a retrospective, population-based study suggest that individuals with lupus who adhere to their antimalarial treatment regimens face reduced risks of developing Type 2 diabetes, which is a common complication associated with the disease. The results of a retrospective, longitudinal study, conducted by researchers from the University of British Columbia (Vancouver, Canada), suggest that individuals with systemic lupus erythematosus (lupus) who adhere to their antimalarial treatment regimens face reduced risks of developing Type 2 diabetes, which is a common complication associated with the disease. Lupus is an autoimmune condition that affects approximately 5 million individuals globally. There is...